Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis
Most patients remain on the therapy for a few months to a year, with adjustments made based on results
doi: 10.3389/fmed.2026.1783429 Received 10 January 2026 Revised 20 April 2026 Accepted 30 April 2026 Published 28 May 2026 Volume 13 - 2026 Edited by Achuthan Raghavamenon, Amala Cancer Research Centre, India Reviewed by Raffaele Carraro, La Princesa University Hospital, Spain Theodoros Androutsakos, National and Kapodistrian University of Athens, Greece Updates Copyright 2026 Wu, Zhang, Ye, Chen, Tung and Zhu
Ask your provider for more detailed information
Get more detailed insights about GLP-1 Drug Market Regional Insights North America : Market Leader in Innovation North America leads in the GLP-1 Drug Market size, accounting for over 50.14% of the global revenue in 2024
several blood and immune system diseases